title: Safety and efficacy of stem cell mobilization under imatinib therapy.
abstract: In order to investigate the safety and efficacy of stem cell mobilization in chronic myeloid leukemia patients under imatinib therapy we treated 10 such patients with granulocyte colony-stimulating factor. We observed that none of the patients developed progressive disease under this treatment. Instead, sufficient CD34+ apheresis could be performed in 7 patients and, as assessed by nested reverse transcriptase polymerase chain reaction (RT-PCR), bcr/abl-negative stem cell products could be generated in 3 patients. Interestingly, in 3 other patients with bcr/abl-positivity in 1st round RT-PCR of peripheral leukocytes, bcr/abl transcripts in stem cell products could only be detected by nested RT-PCR.
authors.forename: Karl-Anton
authors.initials: KA
authors.lastname: Kreuzer
authors.forename: Christine
authors.initials: C
authors.lastname: Klühs
authors.forename: Michaela
authors.initials: M
authors.lastname: Schwarz
authors.forename: Bernd
authors.initials: B
authors.lastname: Dörken
authors.forename: Philipp
authors.initials: P
authors.lastname: Le Coutre
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate